New drug being tested to slow down progression of Alzheimer’s and memory loss


Memories are our own living journal. We can return to pages and relive moments most dear to us. We also use other functions of memory to get through our day. Our ability to retain and form new memories is fundamental to our livelihood.

Nearly 5 million Americans, however, suffer from memory loss as patients of Alzheimer’s and dementia, a collection of symptoms that attacks our ability to remember, think and form new ideas. Simply put, dementia muddles one’s ability to connect with their past, present and future.

A breakthrough study by the T2 Protect Ad is clinically testing the drug troriluzole and its potential effects of protecting against such loss, slowing down and perhaps even improving memory and other mental functions in people suffering from Alzheimer’s.

The study will examine whether troriluzole is effective in the “modulation of glutamate,” which protects against neuron loss and transmits signals from neuron to neuron. The primary objective is to learn more about the drug’s ability to both alleviate symptoms and significantly delay regression. That would be a huge step forward in the development of advanced treatments.

As we learn about advancement in research and treatment for dementia, many caregivers and families are hopeful for the future.

They should be.

At the same time, as an advocate for aging issues and people with dementia, I hope to provide further hope for the immediate. I’m proud to say there are steps we can take today that can provide a better pathway forward. Armed with proper training that focuses on dementia awareness and compassion, caretakers and families alike can reinvent their approach and experience success through the formation of meaningful connections. When we change our viewpoints, our new perspective and expectations lead to better care. Better care means there are more opportunities to enjoy life, focus on our experiences with one another and improve quality of life.

Website Development